Enhancement of bradykinin and resensitization of its B2 receptor

Hypertension

Volumn 33, Issue 3, 1999, Pages 835-843

  Marcic, Branislav ^b   Deddish, Peter A ^b   Jackman, Herbert L ^b   Erdös, Ervin G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitors; Endothelial cells; G proteins; Kininase II; Ca2+ (i)

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRILAT;

ANIMAL CELL; ARACHIDONIC ACID METABOLISM; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 0033034744     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.3.835     Document Type: Article

References (57)

1. Gavras I, Gavras H. ACE inhibitors: a decade of clinical experience. Hosp Pract (Off Ed). 1993;28:117-120, 123, 126-127.
2. Gavras H. Angiotensin converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
3. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94:258-265.
4. Pfeffer MA, Braunwald I, Moye LA, the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
5. Ambrosioni E, Borghi C, Magnani B, the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
6. Lewis EJ. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. In: Koide H, Ichikawa I, eds. Progression of Chronic Renal Diseases. Contrib Nephrol. 1996;118(theme issue):206-213.
7. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new TREND? Circulation. 1996;94:240-243.
8. Yang HYT, Erdös EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J Pharmacol Exp Ther. 1971;177:291-300.
9. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
10. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens B. Reduction in infarct size by local angiotensin converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 1990; 182:395-396.
11. 1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol. 1997;80:110A-117A.
12. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Laragh JH, Brenner BM eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press Publishers; 1995:983-999.
13. Parratt JR, Vegh A, Zeitlin IJ, Ahmad M, Oldroyd K, Kaszala K, Papp JG. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol. 1997;80:124A-131A.
14. Zhang X, Xie Y-W, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 1998;95:176-182.
15. Minshall RD, Erdös EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol. 1997;80:A132-A136.
16. Rabito SF, Minshall RD, Swaminathan B, Tan MN, Igíc R, Erdös EG. Mode of potentiation of the effects of bradykinin by angiotensin I converting enzyme inhibitors on the guinea pig ileum. Anesthesiology. 1998; 89:A635. Abstract.
17. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG. Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors: the role of expressed human bradykinin B2 receptors and ACE in CHO cells. Circ Res. 1997;81: 848-856.
18. Deddish PA, Marcic B, Jackman HL, Wang H-Z, Skidgel RA, Erdös EG. N-domain specific substrates and C-domain inhibitors of angiotensin converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
19. Stewart MJ, Ferreira SH, Greene LJ. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro: an inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem Pharmacol. 1971;20:1557-1567.
20. Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, Wei L, Alhenc-Gelas F. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies: selective inhibition of the amino-terminal active site. J Biol Chem. 1994;269:26806-26814.
21. Tan F, Jackman HL, Harbury P, Deddish PA, Becker RP, Abe M, Skidgel RA, Erdös EG. Identity of human platelet deamidase with lysosomal protective protein (LPP). FASEB J. 1994;8:A1372. Abstract.
22. Jackman HL, Tan F, Tamei H, Beurling-Harbury C, Li X-Y, Skidgel RA, Erdös EG. A peptidase in human platelets that deamidates tachykinins: probable identity with the lysosomal "protective protein." J Biol Chem. 1990;265:11265-11272.
23. 2-induced increase in endothelial permeability. Am J Physiol. 1996;270:L973-L978.
24. Roberts RA, Gullick WJ. Bradykinin receptors undergo ligand-induced desensitization. Biochemistry. 1990;29:1975-1979.
25. Blaukat A, Abd Alla S, Lohse MJ, Müller-Esterl W. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem. 1996;271:32366-32374.
26. 1 MF-2 smooth muscle cells is paralleled by sequestration of the occupied receptors. Arch Biochem Biophys. 1993;301:336-344.
27. 1 MF-2 smooth muscle cells. J Biol Chem. 1987;262:3098-3105.
28. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
29. Schulz WW, Hagler HK, Buja LM, Erdös EG. Ultrastructural localization of angiotensin I-convening enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney. Lab Invest. 1988;59:789-797.
30. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
31. Weare JA, Stewart TA, Gafford JT, Erdös EG. Inhibition of human converting enzyme in vitro by a novel tripeptide analog. Hypertension. 1981;3(suppl I):I-50-I-53.
32. Wyvratt MJ, Patchett AA. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med Res Rev. 1985;5:483-531.
33. Edery H. Further studies of the sensitization of smooth muscle to the action of plasma kinins by proteolytic enzymes. Br J Pharmacol. 1965; 24:485-496.
34. Cîrstea M. Potentiation of some bradykinin effects by thiol compounds. Br J Pharmacol. 1965;25:405-410.
35. Vogel R, Werle E, Zickgraf-Rüdel G. Neure Aspekte der Kininforschung, I: Potenzierung und Blockierung der biologischen Kininwirkung. Z Klin Chem Klin Biochem. 1970;8:177-185.
36. Ufkes JGR, Aarsen PN, van der Meer C. The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle. Eur J Pharmacol. 1977;44:89-97.
37. Auch-Schwelk W, Bossaller C, Claus M, Walther B, Gräfe M, Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res. 1993;27:312-317.
38. Hecker M, Pörsti K, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
39. 2 receptor? Immunopharmacology. 1996;33:93-94.
40. Minshall RD, Vogel SM, Miletich DJ, Erdös EG. Potentiation of the inotropic actions of bradykinin on the isolated guinea pig left atria by the angiotensin I converting enzyme/kininase II inhibitor, enalaprilat. Circulation. 1995;92(suppl I):I-221. Abstract.
41. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RAS. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension. 1997; 30(part 2):542-548.
42. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29(part 2):394-400.
43. Skidgel RA, Erdös EG. Enzymatic breakdown of bradykinin. In: Said SI, ed. Pro-inflammatory and Anti-inflammatory Peptides. New York, NY: Marcel Dekker; 1998:459-476.
44. Snyder RA, Watt KWK, Wintroub BU. A human platelet angiotensin I-processing system: identification of components and inhibition of angiotensin-converting enzyme by product. J Biol Chem. 1985;260: 7857-7860.
45. Skidgel RA, Erdös EG. Biochemistry of angiotensin concerting enzyme. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. Vol 1. London, UK: Gower Medical Publishers; 1993:10.1-10.10.
46. 1 MF-2 smooth muscle cells. J Biol Chem. 1997;272: 17858-17866.
47. Guderman T, Kalkbrenner F, Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol. 1996;36: 429-459.
48. Sternweis PC, Smrcka AV. Regulation of phospholipase C by G proteins. Trends Biol Sci. 1992;17:502-506.
49. Erdös EG, Debay CR, Westerman MP. Arylesterases in blood: effect of calcium and inhibitors. Biochem Pharmacol. 1960;5:173-186.
50. CRAC) in macrovascular endothelial cells: a comparison with Jurkat and embryonic kidney cell lines. Pflugers Arch. 1998;436:69-74.
51. 2+ store: a view from the lumen. Trends Biochem Sci. 1998;23:10-14.
52. Milligan G, Bond RA. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci. 1997;18:468-474.
53. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 1997;80:607-616.
54. +-ATPase endocytosis. J Biol Chem. 1998; 273:8814-8819.
55. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998;273:5419-5422.
56. Margolius HS. Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension. 1995; 26:221-229.
57. Yu H, Carretero OA, Juncos LA, Garvin JL. Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension. 1998;32:287-292.